ALX Oncology Holdings Inc (ALXO)
1.515
+0.02
(+1.68%)
USD |
NASDAQ |
Nov 05, 16:00
1.53
+0.02
(+0.99%)
After-Hours: 19:14
ALX Oncology Holdings Total Liabilities (Quarterly): 55.30M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 55.30M |
| March 31, 2024 | 48.46M |
| December 31, 2023 | 52.84M |
| September 30, 2023 | 51.36M |
| June 30, 2023 | 33.24M |
| March 31, 2023 | 37.75M |
| December 31, 2022 | 43.02M |
| September 30, 2022 | 30.73M |
| June 30, 2022 | 29.70M |
| March 31, 2022 | 20.08M |
| Date | Value |
|---|---|
| December 31, 2021 | 17.13M |
| September 30, 2021 | 14.56M |
| June 30, 2021 | 16.28M |
| March 31, 2021 | 14.43M |
| December 31, 2020 | 6.209M |
| September 30, 2020 | 10.43M |
| June 30, 2020 | 12.47M |
| March 31, 2020 | 9.282M |
| December 31, 2019 | 10.95M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
6.209M
Minimum
Dec 2020
55.30M
Maximum
Jun 2024
27.06M
Average
20.08M
Median
Mar 2022
Total Liabilities (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 1.438B |
| Neurocrine Biosciences Inc | 816.10M |
| Eton Pharmaceuticals Inc | 18.36M |
| Verve Therapeutics Inc | 154.82M |
| Immuneering Corp | 10.78M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 214.62M |
| Shareholders Equity (Quarterly) | 159.32M |